Dexmedetomidine in Off Pump Coronary Artery Bypass Grafting

• Status: Not yet recruiting
• Trial end date: 2023-03-30
• Target enrollment: 0
• Participant gender: All

Summary

the study will assess the impact of intraoperative dexmedetomidine infusion on myocardial performance by investigating the left ventricular (LV) systolic and diastolic function and right ventricular (RV) fraction area change (which reflect RV systolic function) using two-dimensional trans-esophageal echocardiography (TEE) in patients undergoing elective first-time isolated off-pump coronary artery bypass (OPCAB) grafting. LV Systolic function will be measured by the TEE via the fractional area change, fraction shortening, and ejection fraction.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suez Canal University
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Patients undergoing elective first-time off-pump isolated coronary artery bypass graft (OPCAB) surgery

• Patients with good ventricular functions.

• Patients with normal levels of cardiac troponin I and myocardial enzymes

• Patients of Body Mass Index (BMI) more than 20 and less than 34.

Exclusion Criteria:

• Severe functional liver or kidney disease.

• Diagnosed HF (NYHA class >3).

• Arrhythmia or received treatment with anti-arrhythmic drugs.

• Severe bradycardia (HR < 45 bpm) and AV block.

• Pathologic esophageal lesion (esophageal stricture or varix )

• Pregnancy.